Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline • Disease definition • Risk factors for CAD • Diagnosis • Treatment options PART 05: MARKET LANDSCAPE • Market overview • Five forces analysis PART 06: PIPELINE LANDSCAPE PART 07: MARKET SEGMENTATION BY DRUG CLASS • Comparison by drug class • Beta-blockers • Calcium channel blockers • Nitrates • ACE inhibitors • Others • Market opportunity PART 08: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • CAD therapeutics in Americas • CAD therapeutics in EMEA • CAD therapeutics in APAC • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Growing strategic alliances • Investment inclination toward developing countries PART 12: VENDOR LANDSCAPE • Competitive landscape PART 13: VENDOR ANALYSIS • Vendor overview PART 14: KEY VENDORS • AstraZeneca • Gilead • Novartis • Pfizer PART 15: APPENDIX • List of abbreviations Exhibit 01: Symptoms of CAD Exhibit 02: Types of angina Exhibit 03: Few selected risk factors Exhibit 04: Diagnosis and treatment of CAD Exhibit 05: Global CAD therapeutics market snapshot Exhibit 06: Opportunity analysis in global CAD therapeutics market Exhibit 07: Global CAD therapeutics market 2016-2021 ($ millions) Exhibit 08: Five forces analysis Exhibit 09: Pipeline molecules by key vendors Exhibit 10: Key clinical trials Exhibit 11: Global CAD therapeutics market segmentation by drug class 2016-2021 Exhibit 12: Comparison by drug class Exhibit 13: Common beta-blockers used in cardiovascular diseases Exhibit 14: Adverse effects of beta-blockers Exhibit 15: Beta-blockers for CAD treatment – Market size and forecast 2016-2021 ($ millions) Exhibit 16: Beta-blockers for CAD treatment – Year-over-year (YoY) growth 2017-2021 Exhibit 17: Frequent use of beta-blockers in some of the common cardiovascular conditions Exhibit 18: Common calcium channel blockers used for CAD treatment Exhibit 19: Antianginal effects of calcium channel blockers Exhibit 20: Adverse effects of calcium channel blockers Exhibit 21: Calcium channel blockers for CAD treatment – Market size and forecast 2016-2021 ($ millions) Exhibit 22: Calcium channel blockers for CAD treatment – YoY growth 2017-2021 Exhibit 23: Dosage forms of nitrates for CAD treatment Exhibit 24: Nitrates for CAD treatment – Market size and forecast 2016-2021 ($ millions) Exhibit 25: Nitrates for CAD treatment – YoY growth 2017-2021 Exhibit 26: Adverse effects of ACE inhibitors Exhibit 27: ACE inhibitor for CAD treatment – Market size and forecast 2016-2021 ($ millions) Exhibit 28: ACE inhibitors for CAD – YoY growth 2017-2021 Exhibit 29: Other drug classes used in CAD treatment Exhibit 30: Overview of major antiplatelet agents in CAD treatment Exhibit 31: Overview of major anti-ischemic agent in CAD treatment Exhibit 32: Others for CAD treatment – Market size and forecast 2016-2021 ($ millions) Exhibit 33: Others for CAD treatment – YoY growth 2017-2021 Exhibit 34: Geographical segmentation of global CAD therapeutics market 2016-2021 Exhibit 35: Regional comparison Exhibit 36: CAD therapeutics market in Americas 2016-2021 ($ millions) Exhibit 37: CAD therapeutics market YoY growth in Americas 2017-2021 Exhibit 38: CAD therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 39: CAD therapeutics market YoY growth in EMEA 2017-2021 Exhibit 40: CAD therapeutics market in APAC 2016-2021 ($ millions) Exhibit 41: Top Asian countries in terms of population with diabetes Exhibit 42: CAD therapeutics market YoY growth in APAC 2017-2021 Exhibit 43: Key leading countries Exhibit 44: World population by age group: 2015-2050 (millions) Exhibit 45: Percentage of population aged 60 years and above by region 2015 and 2050 Exhibit 46: Major complications of diabetes Exhibit 47: Global obesity facts 2014 Exhibit 48: Side effects of the drugs used in angina pectoris treatment and management Exhibit 49: Demographic and economic snapshot of India and China Exhibit 50: Competitive structure analysis of global CAD therapeutics market Exhibit 51: AstraZeneca: Key highlights Exhibit 52: AstraZeneca: Strength assessment Exhibit 53: AstraZeneca: Strategy assessment Exhibit 54: AstraZeneca: Opportunity assessment Exhibit 55: Gilead: Key highlights Exhibit 56: Gilead: Strength assessment Exhibit 57: Gilead: Strategy assessment Exhibit 58: Gilead: Opportunity assessment Exhibit 59: Novartis: Key highlights Exhibit 60: Novartis: Strength assessment Exhibit 61: Novartis: Strategy assessment Exhibit 62: Novartis: Opportunity assessment Exhibit 63: Pfizer: Key highlights Exhibit 64: Pfizer: Strength assessment Exhibit 65: Pfizer: Strategy assessment Exhibit 66: Pfizer: Opportunity assessment

AstraZeneca, Gilead, Novartis, and Pfizer, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Mylan, and Teva Pharmaceutical Industries